$IOVA 'If M&A continues at this pace, you want to be long Biotech into next year', says Mizuho's Jared Holz. Source: https://t.co/cLUe3XJjLD
This coincides with what many of us believe could be one of the most likely windows for an Iovance acquisition: mid-to-late 2027.
Why?